Pharma

Indoco Remedies Gets USFDA Nod for Generic Rivaroxaban Tablets

Edited By VOH
Published on:
Indoco Remedies Gets USFDA Nod for Generic Rivaroxaban Tablets

Indoco Remedies Limited has received final USFDA approval for its Abbreviated New Drug Application (ANDA) to market Rivaroxaban Tablets USP in 2.5 mg, 10 mg, 15 mg, and 20 mg strengths. These are bioequivalent and therapeutically equivalent to Janssen Pharmaceuticals’ reference drug, Xarelto Tablets, in the same strengths. The approved product will be manufactured at Indoco’s facility in Verna Industrial Area, Goa. Rivaroxaban is prescribed for the treatment of venous thromboembolism (VTE).

FDAIndoco RemediesRivaroxaban

PODCAST

EXPLORE ALL→
Decorative element

Why should

You Choose Us

Get In Touch

Events & Summits

Host or sponsor events that place your brand at the forefront of healthcare impact.

Podcast Features

Engage a wider audience with thought leadership shared across VOH's podcast channels.

Brand Solutions

Take center stage at healthcare forums to spark conversations and share bold perspectives.

Indoco Remedies Gets USFDA Nod for Generic Rivaroxaban Tablets - VOH Network | Voice of Healthcare